Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
- 19 April 2022
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 21 (7) , 873-875
Abstract
Over the last few months, there has been a passionate debate within the scientific community on the risks and the benefits of the vaccines against COVID-19 disease. Reporting relative risk reductio...Keywords
This publication has 15 references indexed in Scilit:
- Safety and Efficacy of NVX-CoV2373 Covid-19 VaccineNew England Journal of Medicine, 2021
- COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the roomThe Lancet Microbe, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsJAMA, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Absolute risk reduction may depend on the duration of the follow-upExpert Review of Clinical Pharmacology, 2015
- Polypill Therapy, Subclinical Atherosclerosis, and Cardiovascular Events—Implications for the Use of Preventive PharmacotherapyJACC, 2014
- The Relation between Blood Pressure and Mortality Due to Coronary Heart Disease among Men in Different Parts of the WorldNew England Journal of Medicine, 2000